Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMS: The aim was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the UK. METHODS AND RESULTS: A total of 1005 patients with de-novo coronary lesions were treated using careful implantation techniques at 24 centers. Follow-up at one year was obtained in 99%. An independent clinical event committee and angiographic corelab adjudicated all events. Patient age was 52 years and 46% presented with acute coronary syndromes. Lesion complexity was B2/C in 47.4%, with an average of 1.4±0.6 BVS implanted and a BVS length of 28±14.3mm. A single BVS was implanted in 71.3%. High pressure post-dilatation was performed in 94.9%, with 50% using intravascular imaging. Device success was achieved in 98.7% and procedure success in 97.3% of patients. At one year, the device-oriented endpoint target lesion failure was 3.2%, and the patient oriented endpoint major adverse cardiac events was 3.4%. Definite ST occurred in 1.4%. By multivariable analysis, scaffold size of 2.5mm predicted ST at one year (OR3.27, 95%CI[1.28,8.37],p=0.014). CONCLUSIONS: With careful patient selection and technique, TLF rates following BVS implantation in real world practice are comparable with contemporary drug eluting stents. ST rates remain high, with small vessel size identified as a contributory factor.

Original publication

DOI

10.4244/EIJ-D-17-00886

Type

Journal article

Journal

EuroIntervention

Publication Date

14/11/2017